Mersana Therapeutics, Inc.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
      • Antibodies
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule

Other Names/Subsidiaries

  • Nanopharma
See more in Biomedtracker

Latest on Mersana Therapeutics, Inc.

Scrip

Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology

 
• By Joseph Haas

Who: Merck KGaA/Caris Life Sciences What: Caris’s research division will discover novel targets for use in cancer antibody-drug conjugate products to be developed by Germany’s Merck. Why: Merck K

Scrip

J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout

 
• By Alaric DeArment

Johnson & Johnson is beginning 2024 by making another bet on antibody-drug conjugates (ADCs) with the acquisition of Ambrx Biopharma, Inc. , which the drug maker announced shortly before CEO Joaquin

Scrip

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

 
• By Mandy Jackson

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI

In Vivo

ADCs Coming Of Age: Deals, Targets And Catalysts

 
• By Lucie Ellis-Taitt

Antibody-drug conjugate (ADC)technology is not new. The first ADC, Pfizer Inc. ’s Mylotarg, reached the market two decades ago. The field has undergone slow but transformative enhancements. “ADC deve